Semiannual Report — FY2026 H1
What JCR Pharmaceuticals Co.,Ltd. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-13View the original on EDINET
How much it says
66Detailed
What moved here
35named for the first time
Its own wording
53terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim consolidated accounting period, revenue decreased year on year to ¥19.974 billion, while research and development expenses increased, resulting in an operating loss, an ordinary loss and an interim net loss attributable to owners of the parent. In terms of funding, cash and cash equivalents decreased from the end of the previous fiscal year, and a commitment line and other arrangements related to the construction of a new formulation plant, as well as the acquisition of property, plant and equipment, are reported.
Komori's summary of this document, not the document's own words.66Detailed
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
70
Detailed
49
Typical
50
Typical
68
Detailed
55
Typical
100
Very detailed
69
Detailed
65
Detailed
50
Typical
R&D spend1,023億円Money spent making new things.
Cash left over-61億円Cash from the business, less what went into equipment.
Spent on equipment78億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.